Wednesday , August 15 2018
Home / Letter From The Editor / June 18, 2016

June 18, 2016

Jun 18, 2016


Most times when you get a Key Opinion Leader and well-known researcher like Dr. George Bakris to talk about trends in drugs, they want all the spotlight. In addition, they often won’t want anything to do with the business side of diabetes. However, due to the close relationship that our Publisher, Steve Freed, has with Dr. Bakris, he was able to get him together with David Kliff, the editor of Diabetic Investor, to talk about the SGLT-2 drugs and how they will affect both healthcare and the cost of healthcare. I am sure you will find this info fascinating, as the two of them offer their own perspectives on what this class of drugs means to the treatment of diabetes.

Announcements: Sunday, June 19, 7PM ET

From “Nat Strand talks food plans for a diabetes-friendly wedding; Chef Michel Nischan cooks up an Italian classic with a healthy twist — Zucchini Parmesan; Jim Turner takes the stage in Jim Turner’s Diabetes Theatre; Delaine Wright flies high on the trapeze with type 1 diabetes.” Sundays live online at at 7 PM ET, 6 PM CT, and 4 PM PT. Keep up on the latest dLife news at


We can make a difference!


Dave Joffe, Editor-in-chief